Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 4/20 | 0.33 |
| ▸ | NOS2 | P35228 | 4/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12975205 | 0.69 | ALDH1A1 (0.36) | CES2POLB | |
| SCHEMBL22473731 | 0.68 | ALDH1A1 (0.33) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27573636 | 0.68 | TAAR1 (0.35) | TAAR1CES2NOS1NOS2NOS3 | |
| SCHEMBL11267030 | 0.67 | TAAR1 (0.40) | TAAR1NOS1NOS2NOS3GBA1 | |
| SCHEMBL10475464 | 0.65 | CALM1 (0.39) | TAAR1NOS1NOS2GBA1 | |
| SCHEMBL6432088 | 0.59 | SLC6A2 (0.44) | TAAR1GBA1 | |
| SCHEMBL31231840 | 0.59 | TLR9 (0.47) | TAAR1GBA1 | |
| SCHEMBL21151453 | 0.57 | ALDH1A1 (0.53) | TAAR1NPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL4357593 | 0.56 | CALM1 (0.45) | GBA1 | |
| Biphenyl SCHEMBL23456981 | 0.55 | ALDH1A1 (0.60) | TAAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447246-B2 | Method of covalently bonding an organic metal complex to a polymer | CYNORA GMBH (DE) | 2016-09-20 | — | — | US | disclosed |
| US-9447246-B2 | Method of covalently bonding an organic metal complex to a polymer | CYNORA GMBH (DE) | 2016-09-20 | — | — | US | disclosed |
| US-20140142259-A1 | METHOD OF COVALENTLY BONDING AN ORGANIC METAL COMPLEX TO A POLYMER | CYNORA GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142259-A1 | METHOD OF COVALENTLY BONDING AN ORGANIC METAL COMPLEX TO A POLYMER | CYNORA GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142259-A1 | METHOD OF COVALENTLY BONDING AN ORGANIC METAL COMPLEX TO A POLYMER | PICALM, LIG4, OSTC | TAAR1 4570/4885CES2 2227/4885NOS1 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.